Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Clinical Advancements of Targeted Antibody-Drug Conjugates in Breast and Lung Cancer

March 31st 2022

This article surveils key advancements in the role of antibody-drug conjugates in solid tumors by examining important clinical trial findings on targeting Trop-2 in breast and lung cancers.

Second-Line Eftilagimod Alpha Plus Pembrolizumab Shows Promising Activity in Metastatic Lung Cancer

March 31st 2022

The combination of eftilagimod alpha and pembrolizumab was found to produce an encouraging early overall survival rate of 73% at the 6-month landmark when used as second-line treatment in patients with PD-1/PD-L1–refractory, metastatic non–small cell lung cancer, according to data from part B of the phase 2 TACTI-002 trial.

Dr. Ramalingam on the Clinical Examination of Patritumab Deruxtecan in NSCLC

March 30th 2022

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the exploration of patritumab deruxtecan in non–small cell lung cancer.

Tiragolumab Plus Atezolizumab/Chemo Misses PFS End Point in Extensive-Stage SCLC

March 30th 2022

The addition of the anti-TIGIT immunotherapy tiragolumab to atezolizumab plus carboplatin/etoposide failed to significantly improve progression-free survival over atezolizumab/chemotherapy alone when used in the frontline treatment of patients with extensive-stage small cell lung cancer, missing the co-primary end point of the phase 3 SKYSCRAPER-02 trial.

European Approval Sought for Neoadjuvant Nivolumab/Chemo in Resectable NSCLC

March 29th 2022

The European Medicines Agency has validated its type II variation application for nivolumab in combination with chemotherapy for use in the neoadjuvant treatment of patients with unresectable stage IB to IIIA non–small cell lung cancer.

Lung Cancer Field Targets Immunotherapy, Acquired Resistance, and Genomic Testing

March 29th 2022

Suresh S. Ramalingam, MD, FACP, FASCO, discusses current applications for frontline immunotherapy and targeted therapy for non–small cell lung cancer and the current management of small cell lung cancer.

Dr. Weksler on Addressing Disparities in Lung Cancer Care Delivery

March 26th 2022

Benny Weksler, MD, MBA, FACS, FACCP, discusses efforts being made at Allegheny Health Network Cancer Institute to address disparities in the delivery of care and its impact on the screening and treatment of lung cancer.

Dr. Bechara on Minimally Invasive Bronchoscopic Approaches in Lung Cancer

March 26th 2022

Rabih I. Bechara, MD, FCCP, discusses how minimally invasive bronchoscopic approaches are utilized in lung cancer.

Experts Survey Treatment Variations for Resectable NSCLC in Asian Populations

March 25th 2022

A panel of lung cancer experts from China, South Korea, and Japan share their insights on how they care for their patients with resectable EGFR-positive non–small cell lung cancer.

Dr. Asbun on the Importance of Multidisciplinary Approaches in Pancreatic Cancer

March 23rd 2022

Horacio J. Asbun, MD, discusses the importance of multidisciplinary approaches in pancreatic cancer.

Dr. Kotecha on MR-Guided Radiotherapy in Lung Cancer

March 23rd 2022

Rupesh Rajesh Kotecha, MD, discusses the use of magnetic resonance–guided radiotherapy in lung cancer.

Adjuvant Pembrolizumab Improves DFS in Stage IB to IIIA NSCLC, Irrespective of PD-L1 Expression

March 18th 2022

Pembrolizumab was found to significantly improve disease-free survival vs placebo when used in the adjuvant treatment of patients with stage IB to IIIA non–small cell lung cancer following surgical resection, meeting 1 of the dual primary end points of the phase 3 KEYNOTE-091 trial.

The Most Important Thing About a Master Plan Is Not Having One: Pasi A. Jänne Is a Giant of Cancer Care in Lung Cancer

March 18th 2022

Pasi A. Jänne, MD, PhD, discovered a new way to treat lung cancer by following his intuition and staying flexible to pursue opportunities as they arise

Dr. Santos on the Utilization of Approved Monotherapies in NSCLC

March 17th 2022

Edgardo S. Santos, MD, FACP, discusses the utilization of approved monotherapies in non–small cell lung cancer.

Dr. Socinski on Treatment Considerations for Difficult-to-Treat Patients in Lung Cancer

March 17th 2022

Mark A. Socinski, MD, executive director, Thoracic Center, medical oncologist, AdventHealth Cancer Institute, discusses therapeutic considerations for difficult-to-treat patients in lung cancer.

FDA Green Lights Companion Diagnostic for EGFR Therapies Targeting Exon 19 Deletions or Exon 21 Alterations in NSCLC

March 17th 2022

The FDA has approved the FoundationOne CDx for use as a companion diagnostic to determine which patients with non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions or exon 21 substitutions may derive benefit from EGFR TKIs that have been greenlit by the agency for this indication.

Toripalimab/Chemo Combo Provides Significant Survival Benefit in NSCLC Without EGFR/ALK Mutations

March 16th 2022

The addition of toripalimab to chemotherapy resulted in improved progression-free survival and overall survival vs chemotherapy alone in patients with treatment-naïve advanced non–small cell lung cancer without EGFR or ALK mutations.

Institutional Perspectives in Cancer- Lung Cancer: Chaired by Jun Zhang, MD, PhD

March 16th 2022

Sugemalimab Shows Efficacy as Consolidation Therapy in Unresectable Stage III NSCLC

March 11th 2022

Sugemalimab significantly prolonged progression-free survival (PFS) vs placebo in Chinese patients with locally advanced, unresectable, stage III non–small cell lung cancer who did not progress after concurrent or sequential chemoradiotherapy.

Frontline Poziotinib Produces Clinically Meaningful Efficacy in NSCLC Harboring HER2 Exon 20 Insertion Mutations

March 7th 2022

Poziotinib elicited encouraging responses when given at a daily dose of 16 mg in the first-line treatment of patients with non–small cell lung cancer with HER2 exon 20 insertion mutations.